BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology.

With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across Southeast Asia (ASEAN) — positioning the Company for long-term growth as precision oncology adoption accelerates across the region.

BGLC has acquired a 15% equity position in Fidelion Diagnostics, the company that holds the exclusive global commercial rights (excluding Greater China) to the VitaGuard™ Tumor-Naïve AI-oncology platform. This investment provides BGLC shareholders with direct participation in Fidelion’s international expansion and future capital markets trajectory, including potential private financing rounds or a future “Qualified Financing Event,” which the agreements specifically include listing on Nasdaq or NYSE as options.

Simultaneously, BGLC has obtained exclusive, perpetual rights to manufacture, market, and distribute VitaGuard™ across all ASEAN markets, solidifying the Company as the sole provider of this advanced liquid biopsy technology in one of the world’s fastest-growing oncology regions.

Southeast Asia’s healthcare landscape is rapidly modernizing, with increasing demand for precision diagnostics and non-invasive tools for cancer management. The VitaGuard™ platform positions BGLC to capture early-mover advantage in this expanding market.

The transaction was structured to maximize balance-sheet strength and minimize dilution:

• Equity Stake (Share Swap): Acquired through a non-cash, share exchange, aligning long-term interests between BGLC and Fidelion.

• Commercial License: The license fee is payable over 24 monthly installments, enabling BGLC to match outflows to expected commercial inflows.

This structure allows BGLC to accelerate market entry, build inventory, and expand regional sales functions while preserving shareholder value.

The completion of this transaction establishes a hybrid value model that is uncommon among micro-cap biotechnology companies:

Through exclusive ASEAN rights, BGLC now controls a high-margin, high-growth cancer diagnostics franchise and has mobilized a commercial task force to engage major hospital networks and distributors across Malaysia, Singapore, Indonesia, and Thailand.

With a 15% equity stake in Fidelion, BGLC gains exposure to the global growth of Fidelion’s AI-driven oncology platform. This equity stake provides structured visibility into Fidelion’s pathway toward future financing milestones or potential liquidity events.

This combined model ensures that BGLC benefits both from immediate commercial activity and long-term enterprise value creation.

“This partnership fundamentally elevates BGLC’s strategic position,” said Sam Tan, CEO of BioNexus Gene Lab Corp. “We are not only securing the engine for commercial growth in Southeast Asia; we are also now aligned as a strategic shareholder in a global AI-oncology platform. This structure gives our shareholders two distinct value levers — regional commercial expansion and exposure to Fidelion’s international growth and capital-market ambitions.”

Mr. Tan added, “We intentionally structured this transaction to preserve our financial strength and avoid unnecessary dilution. As the global precision oncology landscape shifts toward AI-enabled technologies, this partnership positions BGLC at the center of that transformation.”

• Share Swap: BGLC now owns 15% of the issued and outstanding stock of Fidelion Diagnostics while Fidelion holds approximately 16.6% of the issued and outstanding stock of BGLC, which strongly aligns our mutual interests.

• Exclusive License: The ASEAN commercial license is secured for BGLC through the Exclusive Licensing Agreement.

• Operational Mobilization: BGLC and Fidelion will collaborate on regional studies, regulatory engagement, and the introduction of next-generation oncology solutions to the Southeast Asian market.

VitaGuard™ is a next-generation, AI-enabled platform for tumor-naïve minimal residual disease (MRD) monitoring. Designed as a high-efficiency, high-fidelity liquid biopsy system, VitaGuard™ enables clinicians to detect early signs of cancer recurrence and support precision-treatment decision making.

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology company advancing precision diagnostics and gene-based technologies. The Company is building a platform spanning precision medicine, biologics manufacturing, and AI-integrated healthcare solutions, targeting markets in Asia and the United States. For more information, please visit www.bionexusgenelab.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by terminology such as "may," "should," "could," "would," "will," "expect," "anticipate," "intend," "plan," "believe," "estimate," "continue," "potential," and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding: (i) the commercial viability and market acceptance of the VitaGuard™ system in Southeast Asia; (ii) the potential value and future liquidity of the Company’s equity interest in Fidelion Diagnostics, including the likelihood of any future "Qualified Financing Event" or public listing; (iii) the Company’s ability to successfully integrate the new license into its existing operations and meet financial obligations; and (iv) the projected growth of the international MRD testing markets.

These forward-looking statements are based on a number of assumptions, including that: (a) Fidelion Diagnostics will successfully execute its business plan and technology roadmap outside of Greater China; (b) regulatory approvals for VitaGuard™ in ASEAN jurisdictions will be obtained in a timely manner; and (c) market demand for liquid biopsy testing will continue to grow as anticipated. Actual results could differ materially from those anticipated due to risks and uncertainties, including, among others: the risk that Fidelion may not achieve a liquidity event or IPO; the highly competitive nature of the diagnostics industry; and the need for additional BGLC capital to support commercialization. Many of these risks are described in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BGLC undertakes no obligation to publicly update or revise any forward-looking statements.